Rehabilitation of schizophrenic patients

Current Pharmaceutical Design

Volumn 10, Issue 18, 2004, Pages 2277-2288

  Gunatilake, S ^a   Ananth, J ^a,b   Parameswaran, S ^a   Brown, S ^a,c   Silva, W ^a  

^a Metropolitan State Hospital   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c ALLIANT INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Assertive community management; Cognitive remediation; Maintenance antipsychotic treatment; Psychosocial programs; Recovery model of rehabilitaion; Rehabilitation of schizophrenic patients; Social skill training

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; NEUROLEPTIC AGENT;

COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE CONTROL; DISEASE SEVERITY; DRUG MEGADOSE; EDUCATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIFE SATISFACTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MALADJUSTMENT; MENTAL HOSPITAL; MENTAL PATIENT; MOOD DISORDER; MOTIVATION; NEGATIVE SYNDROME; OCCUPATION; PATIENT ATTITUDE; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; PRISON; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SELF ESTEEM; SKILL; SOCIAL INTERACTION; SOCIAL ISOLATION; SOCIAL STATUS; TARDIVE DYSKINESIA; TREATMENT INDICATION;

HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 3042625716     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384141     Document Type: Review

References (115)

1. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003 Feb 1; 361(9355): 417-9.
2. Levinson DF. Molecular genetics of schizophrenia: a review of the recent literature. Curr Opin Psychiatry 2003; 16: 157-170.
3. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry 1986 Jul; 43(7): 633-42.
4. Penn DL, Mueser KT. Research update on psychosocial treatment of schizophrenia. Am J Psychiatry 1996; 153: 607-617.
5. Hornung WP, Kieserg A, Feldman R. Psychoeducational training for schizophrenic patients: background, procedure and empirical findings. Patient Educ Couns 1996; 29: 257-268.
6. Leff J. Working with families of schizophrenic patients. Br J Psychiatry 1994; 164 (suppl 23): 71-76.
7. Hogarty GE, Anderson C, Reiss D, Kornblith S, Greenwald D, Ulrich R, et al. Family psychoeducation, social skills training and maintenance chemotherapy in the after care treatment of schizophrenia II: two year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry 1991; 48: 340-347.
8. Falloon IRH, Boyd JL, McGill CW, Williamson M, Razani J, Moss HB, et al. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two year longitudinal study. Arch Gen Psychiatry 1985, 42: 887-896.
9. Tarrier N, Barrowclough C, Vaughn C, Bamrah JS, Porceddu K, Watts S, et al. Community management of schizophrenia. A two-year follow-up of a behavioural intervention with families. Br J Psychiatry 1989 May; 154: 625-8.
10. Buchkremer G, Schulze Monking H, Holle R, Hornung WP. The impact of therapuetic realtives' groups on the course of illness of schizophrenic patients. Eur Psychiatry 1995; 10: 17-27.
11. Vaughan K, Doyle M, McConaghy N, Balzczynski A, Fox A Tarrier N. The Sydney intervention trial: a controlled trial of relatives counseling to reduce schizophrenic relapse. Soc Psychiatry Psychiatr Epidemiol 1992; 27(1):16-21.
12. Goldstein M.I. Psychoeducational and family therapy in relapse prevention. Acta Psychiatr Scand 1994; 89 (suppl 382): 54-57.
13. Onken SJ, Dumont JM, Ridgway P, Dornan DH, Ralph RO. Phase One Research Report: A National Study of Consumer Perspectives on What Helps and Hinders Mental Health Recovery. Alexandria, VA, National Association of State Mental Health Program Directors, National Technical Assistance Center 2002.
14. Ridgeway P. Restoring psychiatric disability: learning from first person accounts of recovery. Psychiatr Rehabil J 2001; 24(4): 335-343.
15. Ralph RV. Review of recovery literature: a synthesis of a sample of recovery literature 2000. Alexandria, VA, National Technical Assistance Center for State Mental Health Planning 2000.
16. Middelboe T, Mortensen EL. Coping strategies among the long term mentally ill: categorization and clinical determinants. Acta Psychiatr Scand 1997; 96: 188-194.
17. Magliano, L, Guarneri M, Marasco C, Tosini P, Morosini PL, Maj M. A new questionnaire assessing coping strategies in relatives of patients with schizophrenia: development and factor analysis. Acta Psychiatr Scand 1996; 94: 224-228.
18. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998 Feb; 49(2): 196-201.
19. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophr Bull 1991; 17: 197-216.
20. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19(2): 287-302.
21. Marder SR. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA Eds, Psychiatry. Philadelphia, WB Saunders 1997; 1569-85.
22. Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, et al. Use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001; 26: 325-329.
23. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002 Aug; 40(8): 630-9.
24. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000; 102(suppl 407): 83-6.
25. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and Practice of Psychopharmucology. Philadelphia, Lippincott Williams & Wilkins 2001; 43-4.
26. Buckley PF and Melzter HY. Treatment of Schizophrenia. In: Schatzberg AF and Nemeroff CB, eds. Textbook of Psychopharmacology. Washington, DC, American Psychiatric Press 1995; 615-640.
27. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry 1988; 45: 797-805.
28. Kane JM and Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY Ed, Psychopharmacology: The Third Generation of Progress. New York, Raven Press Books 1987; 1103-10.
29. Van Putten T, Marder SR, Minz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47: 754-8.
30. Caffey EM Jr, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. J Chronic Dis 1964 Apr; 17: 347-58.
31. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low and conventional dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 1987; 44: 510-7.
32. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40: 893-6.
33. Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors - a United States perspective. J Clin Psychiatry 1984 May; 45(5 pt. 2): 36-42.
34. Goldstein MJ, Rodnick EH, Evans JR May PR, Steinberg MR. Drug and family therapy ill the aftercare of acute schizophrenics. Arch Gen Psychiatry 1978 Oct; 35(10): 1169-77.
35. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41: 1025-9.
36. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry. 1991 Feb; 48(2): 166-70.
37. Carpenter WT, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144: 1466-70.
38. Herz MI, Szymanski HV, Simon JC. Intermittent medication for stable schizophrenic outpatients: all alternative to maintenance medication. Am J Psychiatry 1982; 139: 918-22.
39. Wiedemann G, Hahlweg K, Muller U, Feinstein E, Hank G, Dose M. Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2001; 251(2):72-84.
40. Gaebel W, Pietzcker A. Prospective study of course of illness in schizophrenia: Part III, Treatment and outcome. Schizophr Bull 1987; 13(2): 307-16.
41. Jolley AG, Hirsch SR, McRink A., Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. Br Med J 1989; 298: 985-90.
42. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at two years. Br Med J 1990; 301; 837-47.
43. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry 1998 Apr; 155(4):565-7.
44. Kane JM, Ritkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70-73.
45. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-7.
46. Kissling W, Ed. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Proceedings of a Consensus Conference Held April 19-20, 1999, in Bruges, Belgium. Berlin: Springer-Verlag, 1991.
47. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy, Drugs 1994; 47: 741-73.
48. Lehman AF and Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations, Schizophr Bull 1998, 24: 1-10.
49. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. In: American Psychiatric Dissociation Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000. Washington DC, American Psychiatric Association 2000; 299-412.
50. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976 Sep; 37(9): 494-500.
51. Cheung HK. Schizophrenics fully remitted oil neuroleptics for 3-5 years - to stop or continue drugs? Br J Psychiatry 1981 Jun, 138: 490-4.
52. Jacobsson L, Odling H. Psychological aspects of depot treatment of schizophrenic syndromes. Lakartidningen 1980 Oct 1; 77(40): 3522-6.
53. Hoencamp E., Knegtering H., Kooij JJS, van der Molen AEGM. Patient requests and attitude towards neuroleptics. Nord J Psychiatry 1995; 49 (suppl. 35):47-55.
54. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997 Jun; 95(6): 464-8.
55. Wistedt, B. How does the psychiatric patient feel about depot treatment, compulsion or help? Nord J Psychiatry 1995; 49 (suppl. 35):41-46.
56. Mueser KT, Bellack AS, Douglas MS, Morrison RL. Prevalence and stability of social skill deficits in schizophrenia. Schizophr Res. 1991 Sep; 5(2): 167-76.
57. Braff DL, Heaton R, Kuck J, Cullum M, Moranville J, Grant I, et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogenous Wisconsin Card Sorting Test results. Arc Gen Psychiatry 1991 Oct; 48(10):891-8.
58. Stratta P, Mancini F, Mattei P, Daneluzzo E, Bustini M, Casacchia M, et al. Remediation of Wisconsin Card Sorting Test performance in schizophrenia. A controlled study. Psychopathology 1997 Mar-Apr; 30(2): 59-66.
59. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up Study. Br J Psychiatry. 2001 Jun; 178: 506-17.
60. Viinamaki H, Niskanen L, Jaaskelainen J, Antiakinen R, Koivumaa-Honkanen H, Lelitonen J: Factors predicting psychosocial recovery in psychiatric patients. Acta Psychiatrica Scand 1996; 94: 365-371.
61. Kupper Z, Hoffman H: Course patterns of psychosocial functioning in schizophrenia patients attending a vocational rehabilitation program. Schizophr Bull 2000; 26: 681-698.
62. Lysaker PH, Bell MD, Ziti WS, Booty SM. Social skills at work. Deficits and predictors of improvement in schizophrenia. J Nerv Ment Dis 1995; 183: 688-692.
63. Bellack AS. A comprehensive model for the treatment of schizophrenia. In: Bellack AS Ed, A Clinical Guide for the Treatment of Schizophrenia. New York, Plenum Press 1989; 1-22.
64. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Association, 1997.
65. Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatr 1998, 43: 25-39.
66. Anthony WA, Forbess R, Cohen MR. Rehabilitation oriented case management. In: Harris M and Bergman H Eds, Case Management for Mentally III Patients: Theory and Practice. Chur, Switzerland, Harwood Academic Publishers 1993; 99-118.
67. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull 2000; 16(1): 21-46.
68. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, et al. Two year Outcome of social skills training and group psychotherapy of outpatients with schizophrenia. Am J Psychiatry 1996; 153: 1585-1592.
69. McKee M, Hill JW, Smith TE. Cognitive and symptom correlates of participation in social skills training groups. Schizophr Res 1997; 23: 223-229.
70. Bowen L, Wallace CJ, Glynn SM, Nuechterlein KH, Lutzker JR, Kuehnel TG. Schizophrenic individuals' cognitive functioning and performance in interpersonal interactions and skills training procedures. J Psychiatr Res 1994; 28: 289-301.
71. Corrigan PW, Wallace CJ, Schade ML, Green MF. Learning medication self management skills in schizophrenia: relationships with cognitive deficits and psychiatric symptoms. Behav Ther 1994; 25: 5-15.
72. Lenzenweger ME, Dworkin RH, Wethington F: Examining the underlying structure of schizophrenic phenomenology: evidence for a three process model. Schizophr Bull 1991; 17: 515-524.
73. Velligan DL, Bow-Thomas C, Mahurin RK, Miller AL, Hagunseth LC: Do specific deficits predict specific domains community function in schizophrenia? J Nerv Ment Dis 2000; 188: 518-524.
74. Pollice R, Roncone R, Falloon IRH, Mazza M, De Rissio A, Necozione S, et al. Is theory of mind in schizophrenia more strongly associated with clinical and social functioning that with neurocognitive deficits? Psychopathology 2002; 35: 280-88.
75. Glynn SM, Marder SR, Liberman RP, Balir K, Wirshing WC, Wirshing D, et al. Supplementing clinic based skills training with manual based community support sessions: effects of social adjustment of patients with schizophrenia. Am J Psychiatry 2002; 159: 829-837.
76. Liberman RP, Wallace CJ, Blackwell G, Kopelwicz A, Vacarro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. Am J Psychiatry 1998; 155: 1087-1091.
77. Atkinson JM, Coia DA, Gilmour WH, Harper JP. The impact of educational groups for people with schizophrenia on social functioning and quality of life. Br J Psychiatry 1996; 168: 199-204.
78. Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: all update. Am J Psychiatry 2001 Feb; 158(2): 163-75.
79. Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, et al. Three year trials of personal therapy among schizophrenic patients living with or independent of family, II: Effect on adjustment of patients. Am J Psychiatry 1997; 54: 1514-1524.
80. Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF, et al, Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: Description of study and effects on relapse rates. Am J Psychiatry 1997 Nov; 154(11): 1504-13.
81. Holloway F, Carson J. Intensive case management for the severely mentally ill: controlled trial. Br J Psychiatry 1998; 172: 19-22.
82. Issadikis C, Sanderson K, Teesson M, Johnston S, Buhrich N. Intensive case management for the severe mental illness in Australia: a randomized controlled trial. Acta Psychiatr Scand 1999; 99: 360-367.
83. Buchkremer G, Klingberg S, Holle R, Schulze Monking H, Hornung WP. Psychoeducational psychotherapy for schizophrenic patients and their key relatives or care-givers: results of a 2-year follow-up. Acta Psychiatr Scand 1997 Dec; 96(6): 483-91.
84. Ruud T, Martinsen EW, Friis S. Chronic patients in psychiatric institutions: psychopathology, level of functioning and need for care. Acta Psychiatr Scand 1998; 97: 55-61.
85. Baker R, Hall JN. Users Manual for Rehabilitation Evaluation of Hall and Baker. Aberdeen, Vine Publishing 1986.
86. Montero I, Ruiz Perez I, Gomez Beneyto M: Social adjustment in schizophrenia: Factors predictive of short term social adjustment in a sample of schizophrenic patients Acta Psychiatr Scand 1998; 97:116-121.
87. Lenoir M, Peter MA, Dingemans MAJ, Linzen DH, Lieuwe De Haan, Schene AH. Social functioning and the Course of early onset schizophrenia. Brs J Psychiatry 2001; 179: 52-58.
88. Sellwood W, Tarrier N, Quinn J, Borrowclough C. The Family and compliance in schizophrenia: the influence of clinical variables, relatives' knowledge and expressed emotion. Psychol Med 2003; 33: 91-96.
89. Huxley NA, Rendall M, Sederer L. Psychosocial treatments in schizophrenia. J Nerv Ment Dis 2000; 188: 187-201.
90. McFarlane WR, Kukens E, Link B, Dushay R, Deakens SA, Newmark M, et al. Multiple family groups and psychoeducation in the treatment of schizophrenia. Arch Gen Psychiatry 1995; 52: 679-687.
91. Lam DH, Psychosocial family intervention in schizophrenia: a review of empirical studies. Psychol Med. 1991 May; 21(2): 423-41.
92. Kottgen C, Sonniehsen I, Molenhauser K, Jurth R. Group therapy with families of schizophrenic patients III . Results of the Hamburg Camberwell family interview study. International Journal of Family Therapy 1984; 5: 84-94.
93. Mueser KT, Bond GR, Drake RE, Redneck SG. Models of community care for severe mental illness: A review of research on case management. Schizophr Bull 1998; 24(1): 37-74,
94. Kanter J. Clinical case management: Definition, principles and components. Hosp Community Psychiatry 1989; 40: 361-368.
95. Stein LI, Test MA: Alternative to mental hospital treatment I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392-397.
96. Lehman AF, Goldberg R, Dixon LB, McNary S, Postrado L, Hackman A, et al. Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry 2002, 59: 163-172.
97. Lysaker PH, Bell M. Work rehabilitation and improvements in insight in schizophrenia. J Nerv Ment Dis 1995; 183: 103-106.
98. Bond GR, Dietzen LL, McGraw JH, Miller LD. Accelerating entry into supported employment for persons with severe psychiatric disabilities. Rehab Psychol 1995; 40: 91-111.
99. Drake RE, McHugo GJ, Bebout RR, Becker DR, Harris M, Bond GR, et al. A randomized clinical trial of supported employment for inner city patients with severe mental disorders. Arch Gen Psychiatry 1999; 56: 627-633.
100. Friedman JI, Harvey PD, McGurk SR, White L, Parrella M, Raykov T, et al. Correlates of changes in functional status of institutionalized geriatric schizophrenic patients" Focus on medical comorbidity. Am J Psychiatry 2002; 159: 1388-1394.
101. Wykes T, Brammer M, Mellers J, Bray P, Reeder C, Williams C, Corner J. Effects on the brain of psychological treatment: cognitive remediation therapy. Br J Psychiatry 2002 Aug; 181: 144-52.
102. Penadés R, Boget T, Lomena F, Mateos JJ, Catalan R, Gastro C, et al. Could the hypofrontality pattern in schizophrenia be modified through neuropsychological rehabilitation? Acta Psychiatr Scand 2002; 105: 202-208.
103. Kuipers E, Garety P, Fowler D, Dunn G, Bebbington P, Freeman D, et al. London-East Anglia randomized controlled trial of cognitive behavioral therapy for psychosis effects of treatment phase. Br J Psychiatry 1997; 171: 319-327.
104. Tarrier N, Yusupoff L, Kinney C, McCarthy F, Gledhill A, Haddock G, et al. Randomized controlled trial of intensive cognitive behavioral therapy for patients with chronic schizophrenia. Br Med J 1998; 317: 303-307.
105. Sensky T, Torrington D, Kingdom D, Scott JL Scott J, Saddle R, et al. A randomized controlled trial of cognitive behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 200; 57: 165-172.
106. Bradshaw W. Integrating cognitive behavioral psychotherapy for persons with schizophrenia into a psychiatric rehabilitation program: results of three year trial. Community Merit Health J 2000; 38: 491-500.
107. Kurtz MM. Neurocognitive rehabilitation for schizophrenia. Curr Psychiatry Rep 2003, 5: 303-310.
108. Krabbendam L, Aleman A. Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies. Psychopharmacology (Berl). 2003 Sep; 169(3-4): 376-82.
109. Medalia A, Revheim N, Casey M. The remediation of problem solving skills in schizophremia. Schizophr Bulletin 2001; 27(2): 259-267.
110. Roder V, Brenner HD, Muller D, Lachler M, Zorn P, Reisch T, et al. Development of specific social skills training programs for schizophrenia patients: results of a multicenter study. Acta Psychiatr Scand 2002; 105: 363-371.
111. Medina J. Exercise and cognition. Psychiatric Times 2003; 10(9): 17-18.
112. Brekke JS, Kohrt B, Green MF. Neuropsychological functioning as a measure of moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bulletin 2001; 27(4): 697-708.
113. Covelli V, Pellegrino NM, Jirillo E. A point of view: The need to identify an antigen in psyconeuroimmunological disorders. Curr Pharm Design 2003; 9(24): 1951-5.
114. Ito C. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia, Curr Pharm Design 2002; 8(2): 147-53.
115. Luedtkea RR, Mach RH. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Design 2003; 9(8). 643-71.